![](https://endpts.com/wp-content/uploads/2023/12/Paul-Hudson-Sanofi-AP-tile1.jpg)
Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA/Sipa via AP Images)
FTC expands pharma scrutiny to early-stage deals, forcing Sanofi to drop Pompe disease partnership with Maze
The Federal Trade Commission said it would seek to block Sanofi’s proposed licensing deal for Maze Therapeutics’ clinical-stage Pompe disease treatment, leading the French pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.